{"DataElement":{"publicId":"3828984","version":"1","preferredName":"Vaccine Therapy Administered Type","preferredDefinition":"The type of vaccination administered.","longName":"VACCINE_TX_ADMIN_TP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3613425","version":"1","preferredName":"Vaccine Therapy Administered","preferredDefinition":"information related to the administration of a vaccine therapy.","longName":"2486738v1.0:2239847v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2486738","version":"1","preferredName":"Vaccine Therapy","preferredDefinition":"Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.","longName":"C15347","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccine Therapy","conceptCode":"C15347","definition":"Immunotherapy using a preparation that usually contains a complex mixture of disease-related antigens, immunopotentiating agents, and immunomodulators, which stimulate the immune system to destroy pathogenic microorganisms or tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1620EC2C-3B38-4FF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-13","endDate":null,"createdBy":"PWEST","dateCreated":"2006-06-13","modifiedBy":"ONEDATA","dateModified":"2006-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBCF222C-DC05-C95F-E040-BB89AD43487C","latestVersionIndicator":"Yes","beginDate":"2012-10-11","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-10-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3828973","version":"1","preferredName":"Vaccine Type","preferredDefinition":"Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer._Something distinguishable as an identifiable class based on common qualities.","longName":"VACCINE_TP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"H. Influenzae","valueDescription":"Haemophilus Influenzae B Vaccine","ValueMeaning":{"publicId":"3828974","version":"1","preferredName":"Haemophilus Influenzae B Vaccine","longName":"3828974","preferredDefinition":"A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib).  Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine.  These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Haemophilus Influenzae B Vaccine","conceptCode":"C1126","definition":"A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2D43-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2D5C-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"Flu shot","valueDescription":"Trivalent Influenza Vaccine","ValueMeaning":{"publicId":"3828976","version":"1","preferredName":"Trivalent Influenza Vaccine","longName":"3828976","preferredDefinition":"A synthetic vaccine consisting of three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. This agent may be formulated for injection or intranasal administration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trivalent Influenza Vaccine","conceptCode":"C2643","definition":"A synthetic vaccine consisting of hemagglutinin (HA) antigens derived from three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine (TIV) is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. Upon administration, the TIV provides active immunization against the three influenza virus strains, thereby protecting against influenza infection. A form of TIV containing higher concentrations of HA antigens may be used in older patients to elicit a more effective immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2D69-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2D82-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"DT","valueDescription":"Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed","ValueMeaning":{"publicId":"3828978","version":"1","preferredName":"Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed","longName":"3828978","preferredDefinition":"A vaccine containing detoxified tetanus toxoid and detoxified diphtheria toxoid adsorbed on aluminum phosphate with active immunizing activity against diphtheria and tetanus. Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin and diphtheria toxin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed","conceptCode":"C91718","definition":"A vaccine containing detoxified tetanus toxoid and detoxified diphtheria toxoid adsorbed on aluminum phosphate with active immunizing activity against diphtheria and tetanus. Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin and diphtheria toxin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2D8F-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2DA8-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"Pneumoax","valueDescription":"Pneumococcal Polyvalent Vaccine","ValueMeaning":{"publicId":"3828979","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine","longName":"3828979","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2DB2-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2DCB-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"MMR","valueDescription":"Measles/Mumps/Rubella Vaccine","ValueMeaning":{"publicId":"3828981","version":"1","preferredName":"Measles/Mumps/Rubella Vaccine","longName":"3828981","preferredDefinition":"A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella. It is an injection administered subcutaneously in two separate doses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measles/Mumps/Rubella Vaccine","conceptCode":"C96403","definition":"A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella. It is an injection administered subcutaneously in two separate doses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2DD8-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2DF1-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"Polio","valueDescription":"Polio Vaccination","ValueMeaning":{"publicId":"3828983","version":"1","preferredName":"Polio Vaccination","longName":"3828983","preferredDefinition":"The administration a series of either live or inactivated poliovirus for the prophylaxis of poliomyelitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polio Vaccination","conceptCode":"C96409","definition":"The administration a series of either live or inactivated poliovirus for the prophylaxis of poliomyelitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2DFE-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2E17-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"Hepatitis B","valueDescription":"Hepatitis B Vaccine","ValueMeaning":{"publicId":"2578114","version":"1","preferredName":"Hepatitis B Vaccine","longName":"2578114","preferredDefinition":"A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle.  Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis B Vaccine","conceptCode":"C29091","definition":"A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2E2B-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"Hepatitis A","valueDescription":"Hepatitis A Vaccine","ValueMeaning":{"publicId":"2578113","version":"1","preferredName":"Hepatitis A Vaccine","longName":"2578113","preferredDefinition":"An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV).  Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis A Vaccine","conceptCode":"C29090","definition":"An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A8BB67-2E40-B6D0-E040-BB89AD43093C","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C71BAD22-043B-14D8-E053-4EBD850A0409","beginDate":"2021-07-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-14","modifiedBy":"ONEDATA","dateModified":"2021-07-14","deletedIndicator":"No"},{"value":"Covid-19 vaccine","valueDescription":"COVID-19 Vaccine","ValueMeaning":{"publicId":"7740207","version":"1","preferredName":"COVID-19 Vaccine","longName":"7740207","preferredDefinition":"Any vaccine that may prevent coronavirus disease-2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COVID-19 Vaccine","conceptCode":"C173023","definition":"Any vaccine that may prevent coronavirus disease-2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C71BAD22-0445-14D8-E053-4EBD850A0409","latestVersionIndicator":"Yes","beginDate":"2021-07-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-14","modifiedBy":"ONEDATA","dateModified":"2021-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C71BAD22-045E-14D8-E053-4EBD850A0409","beginDate":"2021-07-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-14","modifiedBy":"ONEDATA","dateModified":"2021-07-14","deletedIndicator":"No"},{"value":"GAd20-209-FSP","valueDescription":null,"ValueMeaning":{"publicId":"10457691","version":"1","preferredName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","longName":"10457691v1.00","preferredDefinition":"An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","conceptCode":"C162805","definition":"An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0CF7FDC-AC61-2FB0-E053-731AD00A00D0","latestVersionIndicator":"Yes","beginDate":"2022-06-09","endDate":null,"createdBy":"LISU","dateCreated":"2022-06-09","modifiedBy":"LISU","dateModified":"2022-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E0CF7FDC-AC63-2FB0-E053-731AD00A00D0","beginDate":"2022-06-09","endDate":null,"createdBy":"LISU","dateCreated":"2022-06-09","modifiedBy":"LISU","dateModified":"2022-06-09","deletedIndicator":"No"},{"value":"MVA-209-FSP","valueDescription":null,"ValueMeaning":{"publicId":"10457692","version":"1","preferredName":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","longName":"10457692v1.00","preferredDefinition":"An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","conceptCode":"C162806","definition":"An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0CF7FDC-AC62-2FB0-E053-731AD00A00D0","latestVersionIndicator":"Yes","beginDate":"2022-06-09","endDate":null,"createdBy":"LISU","dateCreated":"2022-06-09","modifiedBy":"LISU","dateModified":"2022-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E0CF7FDC-AC64-2FB0-E053-731AD00A00D0","beginDate":"2022-06-09","endDate":null,"createdBy":"LISU","dateCreated":"2022-06-09","modifiedBy":"LISU","dateModified":"2022-06-09","deletedIndicator":"No"},{"value":"Tdap","valueDescription":null,"ValueMeaning":{"publicId":"7356955","version":"1","preferredName":"Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed","longName":"7356955","preferredDefinition":"A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. The acellular pertussis vaccine components, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and B. pertussis antigens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed","conceptCode":"C91717","definition":"A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. The acellular pertussis vaccine components, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and B. pertussis antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D7D4-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6CB5A0C-12F0-394B-E053-731AD00A6FFE","beginDate":"2023-03-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-13","modifiedBy":"MMADDINENI","dateModified":"2023-03-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2831222","version":"1","preferredName":"Vaccine Therapy","preferredDefinition":"Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.","longName":"C15347","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6206C3D8-38E9-7329-E040-BB89AD436A24","latestVersionIndicator":"Yes","beginDate":"2009-02-03","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-03","modifiedBy":"CURTIST","dateModified":"2009-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3828972","version":"1","preferredName":"Vaccine Type","preferredDefinition":"Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.:Something distinguishable as an identifiable class based on common qualities.","longName":"C923:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2D1B-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"ONEDATA","dateModified":"2013-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2D2C-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"MMADDINENI","dateModified":"2023-03-13","changeDescription":"Created for Survival/Death CRFs.","administrativeNotes":"03/13/2023-Added PV-CADSR0002133-MM","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Type of Vaccination","type":"Preferred Question Text","description":"Type of Vaccination","url":null,"context":"NCIP"},{"name":"DCP-Text-1","type":"Alternate Question Text","description":"Vaccine","url":null,"context":"DCP"}],"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2E51-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"LISU","dateModified":"2022-06-09","changeDescription":"Curated for Survival/Death CRF. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}